Abstract
A tiny drug-eluting device that sits in a brain tumor for the duration of a patient's surgery has shown promise as a clinical tool for guiding personalized treatment decisions. A pilot trial in high-grade gliomas found that the device was safe and could reveal early molecular indicators of drug action.
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.